Mylan announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for Cabergoline Tablets. 

Cabergoline is a dopamine agonist indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

RELATED: Endocrine Disorders Resource Center

Cabergoline is a synthetic ergot alkaloid and an ergoline derivate with long-acting dopamine agonist and prolactin-inhibiting properties. A central dopaminergic effect via D2-receptor stimulation is achieved through higher doses than doses that reduce the levels of serum prolactin. The prolactin-reducing effect is dose-dependent.

Mylan’s Cabergoline Tablets are available in a 0.5mg strength.

For more information call (800) RX-MYLAN or visit